By PG In NewsPosted May 20, 2020 Sentien CEO Brian Miller Interviewed About Pursuing SBI-101 Treatment for COVID-19 Patients Read More
By PG In Press ReleasesPosted May 15, 2020 Sentien Biotechnologies Names Richard Ganz as Executive Chairman LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced the appointment of Richard Ganz as Executive [...] Read More
By PG In NewsPosted May 12, 2020 Sentien to Present SBI-101 Clinical Data in AKI at 2020 ASGCT Annual Meeting that Supports Expansion to COVID-19 Read More
